The verdict
Our read at a glance.
Whether eptifibatide's approved antiplatelet role in acute coronary syndrome and PCI is understood within that specific setting, rather than generalized.
- The signal
- Randomized trials, including PURSUIT and ESPRIT, supported eptifibatide for reducing ischemic events in acute coronary syndrome and during percutaneous coronary intervention. Bleeding is the main trade-off, and its use has evolved with newer oral antiplatelet drugs.
- The unknown
- Its place now that potent oral antiplatelet agents are standard, and the best patient selection to balance ischemic benefit against bleeding.
- Our read
- A hospital antiplatelet drug for acute heart events, not something used outside that setting. Eptifibatide has real trial support in acute coronary syndrome and PCI, with bleeding as the central trade-off.
The mechanism
How it works.
Eptifibatide is a synthetic cyclic peptide that plugs the glycoprotein IIb/IIIa receptor on the surface of platelets. That receptor is the final common step platelets use to bind fibrinogen and link to each other, so blocking it stops platelets from clumping into a clot no matter what triggered them. It is given by IV during acute coronary events and stenting and reverses within hours once the drug is stopped.
Safety & regulatory boundary
The consequential part.
Eptifibatide increases bleeding risk and can cause thrombocytopenia (low platelets), and it is contraindicated in several bleeding-related situations. It is a hospital-administered drug for specific acute cardiology indications. Integrilin and other eptifibatide products are not the same as compounded or research-labeled eptifibatide, and the approved use does not extend to any general or wellness setting.
What's next
What we're watching.
Its evolving role alongside oral antiplatelet drugs, and patient-selection and bleeding-management data.
Context
Why this is discussed.
Eptifibatide is one of the intravenous antiplatelet agents used in acute heart conditions and during stenting.
The evidence base
23 cited references.
Regulatory & labels3
Eugia US LLC (FDA label) · 2024
Slate Run Pharmaceuticals, LLC (FDA label) · 2026
Meitheal Pharmaceuticals Inc. (FDA label) · 2024
Registered trials8
ClinicalTrials.gov · PHASE3 · NOT_YET_RECRUITING · 2026-03-01
ClinicalTrials.gov · PHASE3 · COMPLETED · 2019-10-15
ClinicalTrials.gov · PHASE3 · COMPLETED · 2004-11-01
ClinicalTrials.gov · PHASE1/PHASE2 · UNKNOWN · 2022-02-18
ClinicalTrials.gov · RECRUITING · 2022-01-10
ClinicalTrials.gov · WITHDRAWN · 2013-10
ClinicalTrials.gov · PHASE2 · COMPLETED · 2012-04
ClinicalTrials.gov · PHASE2 · COMPLETED · 2016-11-01
Indexed literature (PubMed)12
Pang X et al. · Signal Transduct Target Ther · 2023
Adeoye O et al. · N Engl J Med · 2024
Vayne C et al. · J Clin Med · 2020
PubMed · 2006
Hamm CW · Annu Rev Med · 2003
Brown DL et al. · Am J Cardiol · 2001
Parakh S et al. · Int J Cardiol · 2009
Liu J et al. · J Thromb Thrombolysis · 2022
Carretta LTA et al. · J Thromb Thrombolysis · 2025
Huang J et al. · J Hematol Oncol · 2019
Zhou X et al. · J Evid Based Med · 2017
Zhu X et al. · Clin Appl Thromb Hemost · 2020
Keep reading